60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
60 Degrees Pharma filed an 8-K on July 9th, likely with financial updates. Keep an eye out for details.
AI Summary
On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that 60 Degrees Pharmaceuticals, Inc. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information about significant financial distress, major operational changes, or negative market events.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- July 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-41719 (filing_id) — Commission File Number
- 45-2406880 (tax_id) — IRS Employer Identification Number
- 1025 Connecticut Avenue NW, Suite 1000 Washington , D.C. 20036 (address) — Registrant's principal executive office
FAQ
What specific "Other Events" are being reported by 60 Degrees Pharmaceuticals, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the details of the "Other Events" beyond listing the item information category.
What is the significance of the "Financial Statements and Exhibits" being listed as an item in this 8-K?
This indicates that the filing includes or updates financial statements and exhibits, which are crucial for investors to assess the company's financial health and performance.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 9, 2024.
What is the principal executive office address for 60 Degrees Pharmaceuticals, Inc.?
The principal executive office address for 60 Degrees Pharmaceuticals, Inc. is 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036.
What is the SIC code for 60 Degrees Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for 60 Degrees Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 878 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-07-09 15:37:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SXTP The Nasdaq Stock Market LLC
Filing Documents
- ea0209161-8k_60degrees.htm (8-K) — 34KB
- ea020916101ex99-1_60degrees.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-060093.txt ( ) — 280KB
- sxtp-20240709.xsd (EX-101.SCH) — 4KB
- sxtp-20240709_def.xml (EX-101.DEF) — 26KB
- sxtp-20240709_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240709_pre.xml (EX-101.PRE) — 25KB
- ea0209161-8k_60degrees_htm.xml (XML) — 6KB
Forward-Looking Statements
Forward-Looking Statements This Item 8.01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely historical (including, but not limited to "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such goals, beliefs, plans, expectations or intentions will prove to be accurate, including but not limited to the results of the study described in this Item 8.01. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission. The information set forth under this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial
Item 9.01 Financial (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of July 9, 2024 . 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: July 9, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2